|
SPATA5L1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.44440032051807E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.30270000342492E-08 |
| Normal-vs-Stage2 |
5.67980000000246E-05 |
| Normal-vs-Stage3 |
5.15850000493145E-08 |
| Normal-vs-Stage4 |
7.23930004831175E-09 |
| Stage1-vs-Stage2 |
5.475600E-01 |
| Stage1-vs-Stage3 |
2.316600E-01 |
| Stage1-vs-Stage4 |
4.012400E-02 |
| Stage2-vs-Stage3 |
8.886600E-01 |
| Stage2-vs-Stage4 |
3.639800E-01 |
| Stage3-vs-Stage4 |
2.846000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.88227211594949E-12 |
| Normal-vs-AfricanAmerican |
4.931900E-02 |
| Normal-vs-Asian |
8.784500E-03 |
| Caucasian-vs-AfricanAmerican |
7.021500E-02 |
| Caucasian-vs-Asian |
1.721700E-03 |
| AfricanAmerican-vs-Asian |
9.861400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
8.30969999476849E-08 |
| Normal-vs-Female |
8.98149998818099E-10 |
| Male-vs-Female |
8.563400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.22709999833748E-08 |
| Normal-vs-Age(41-60Yrs) |
1.07690000028526E-07 |
| Normal-vs-Age(61-80Yrs) |
2.05100000316705E-08 |
| Normal-vs-Age(81-100Yrs) |
1.062790E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.709600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.558830E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.684950E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.226400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.369400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.660600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
9.177700E-03 |
| Classical-VS-Follicular |
7.411600E-01 |
| Classical-VS-Other |
9.004400E-01 |
| Classical-VS-Normal |
6.65629995566519E-09 |
| Tall-VS-Follicular |
1.084630E-01 |
| Tall-VS-Other |
5.231800E-01 |
| Tall-VS-Normal |
5.97579996597375E-09 |
| Follicular-VS-Other |
9.966200E-01 |
| Follicular-VS-Normal |
1.8652600000002E-05 |
| Other-VS-Normal |
3.855600E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.99289999847485E-08 |
| Normal-vs-N1 |
1.26160000002429E-07 |
| N0-vs-N1 |
2.939600E-01 |
|
|
